High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer-Reference-Cited by-同舟云学术

High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer

Published:2017-07-17 Issue:7 Volume:12 Page:e0181125
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Silva Estela Maria,Mariano Vânia Sammartino^ORCID,Pastrez Paula Roberta Aguiar,Pinto Miguel Cordoba,Castro António Gil,Syrjanen Kari Juhani,Longatto-Filho Adhemar

Funder

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Fundação de Amparo à Pesquisa do Estado de São Paulo

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference46 articles.

1. Cancer statistics, 2014;R Siegel;CA Cancer J Clin,2014

2. Classification and Pathology of Lung Cancer;M Zheng;Surg Oncol Clin N Am,2016

3. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?;M Reck;Ann Oncol,2012

4. The Treg/Th17 paradigm in lung cancer;MC Duan;J Immunol Res,2014

5. Targeting the immune system in the treatment of non-small-cell lung cancer;D Rangachari;Curr Treat Options Oncol,2013

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ginsenoside CK ameliorates tumor growth in lung cancer mice via inhibiting EGFR;Journal of Functional Foods;2024-10

2. Interleukin-6 in relation to early recurrence in primary, localized soft tissue sarcoma: An addition for existing risk classification systems?;European Journal of Surgical Oncology;2024-09

3. Immune Checkpoint Inhibitors in Cancer Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28

4. Description of lymphocyte and cytokine profiles in individuals with acute myeloid leukemia associated with FLT3-ITD and NPM1 mutation status;European Journal of Cancer Prevention;2024-06-21

5. Immunomodulatory gene polymorphisms in non-small cell lung carcinoma susceptibility and survival;Heliyon;2024-06